Blood Sample

HOW OUR TECHNOLOGY WORKS

Melio’s patented breakthrough technology has been validated by multiple peer reviewed journals and clinicians. Our platform profiles each pathogen cell present in the blood sample by way of thousands of parallel reactions, capturing their unique DNA melting profile. This data is then analyzed with an on-device computer to provide accurate and quick identification of the pathogen(s). Melio’s platform allows for the identification of common bacterial, fungal and viral targets in the blood sample in under 3 hours, accelerating treatment and patient outcomes.

PUBLICATIONS

MASSIVELY PARALLEL DIGITAL HIGH RESOLUTION MELT FOR RAPID AND ABSOLUTELY QUANTITATIVE SEQUENCE PROFILING

February 8, 2017

We report the development of an integrated platform enabling the identification of bacterial pathogen DNA sequences in complex samples in less than four hours.

EMERGING TECHNOLOGIES FOR MOLECULAR DIAGNOSIS OF SEPSIS

February 28, 2018

We outline the limitations of routine blood culture testing and discuss how emerging sepsis technologies are converging on the characteristics of the ideal sepsis diagnostic test.

A HIGH-RESOLUTION DIGITAL DNA MELTING PLATFORM FOR ROBUST SEQUENCE PROFILING AND ENHANCED GENOTYPE DISCRIMINATION

April 13, 2018

These studies show that reliable high-resolution melt curve genotyping can be achieved in digital, picoliter-scale reactions and demonstrate that rate-dependent melt signatures may be useful for enhancing automated melt genotyping.

IMPROVING QUANTITATIVE POWER IN DIGITAL PCR THROUGH DIGITAL HIGH-RESOLUTION MELTING

May 26, 2020

We use a custom digital platform to assess the utility for mitigation of false positives and false negatives in dPCR. We show that detection of an internal control reduces the inclusion of false-negative partitions, changing the calculated DNA concentration up to 52%.

DATA-DRIVEN NOISE MODELING OF DIGITAL DNA MELTING ANALYSIS ENABLES PREDICTION OF SEQUENCE DISCRIMINATING POWER

December 23, 2020

Our toolbox enables the in silico design and testing of broad-based screening assays and the selection of optimal classifiers.